Cargando…

Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an inflammatory disease of the joints, which causes severe pain and excessive systemic circulation of harmful inflammatory cytokines. Current treatments are limited, with some patients not responding well, and some experiencing severe and detrimental side effects. Mesenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Linan, Farhoodi, Henry P., Han, Menglu, Liu, Guangyang, Yu, Jingxia, Nguyen, Lily, Nguyen, Brenda, Nguyen, Agnes, Liao, Wenbin, Zhao, Weian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784581/
https://www.ncbi.nlm.nih.gov/pubmed/33054324
http://dx.doi.org/10.1177/0963689720965896
_version_ 1783632319296307200
author Liu, Linan
Farhoodi, Henry P.
Han, Menglu
Liu, Guangyang
Yu, Jingxia
Nguyen, Lily
Nguyen, Brenda
Nguyen, Agnes
Liao, Wenbin
Zhao, Weian
author_facet Liu, Linan
Farhoodi, Henry P.
Han, Menglu
Liu, Guangyang
Yu, Jingxia
Nguyen, Lily
Nguyen, Brenda
Nguyen, Agnes
Liao, Wenbin
Zhao, Weian
author_sort Liu, Linan
collection PubMed
description Rheumatoid arthritis (RA) is an inflammatory disease of the joints, which causes severe pain and excessive systemic circulation of harmful inflammatory cytokines. Current treatments are limited, with some patients not responding well, and some experiencing severe and detrimental side effects. Mesenchymal stem cells (MSC) are cell-based therapeutics being evaluated as potent immunomodulators in RA and may provide relief to patients not responding well to drug-based treatments. We evaluated the safety and efficacy of BX-U001 human umbilical cord tissue–derived mesenchymal stem cells (hUC-MSC) to treat RA, in support of a successful investigational new drug application. A collagen-induced arthritis (CIA) mouse model of RA was established in DBA/1 J mice. Mice from the treatment assessment group were given a tail vein infusion of hUC-MSC 24 days after primary RA induction, while control assessment (CA) group mice were given cell-free carrier solution. All animals were evaluated daily for RA symptoms via clinical scoring, blood was taken periodically for cytokine analysis, and mice were dissected at end point for histological analysis. A linear mixed model was used to compare the rate of change among groups. The clinical scores of TA group were significantly reduced compared with CA group (P < 0.01), indicating therapeutic effects. The histological scores of the joints in TA group were significantly lower than those in the CA group (P < 0.05), but had no significant difference compared with Healthy groups (P > 0.05). The concentration of (interleukin) IL-6 in TA group was significantly reduced by 80.0% (P < 0.0001) 2 days after treatment and by 93.4% at the experimental endpoint compared with levels prior to hUC-MSC injection. A single intravenous infusion of hUC-MSC (2 × 10(6) cells/mouse), to CIA-induced DBA/1 J mice, resulted in significant alleviation of RA symptoms and may provide significant therapeutic benefits in humans.
format Online
Article
Text
id pubmed-7784581
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77845812021-01-14 Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis Liu, Linan Farhoodi, Henry P. Han, Menglu Liu, Guangyang Yu, Jingxia Nguyen, Lily Nguyen, Brenda Nguyen, Agnes Liao, Wenbin Zhao, Weian Cell Transplant Original Article Rheumatoid arthritis (RA) is an inflammatory disease of the joints, which causes severe pain and excessive systemic circulation of harmful inflammatory cytokines. Current treatments are limited, with some patients not responding well, and some experiencing severe and detrimental side effects. Mesenchymal stem cells (MSC) are cell-based therapeutics being evaluated as potent immunomodulators in RA and may provide relief to patients not responding well to drug-based treatments. We evaluated the safety and efficacy of BX-U001 human umbilical cord tissue–derived mesenchymal stem cells (hUC-MSC) to treat RA, in support of a successful investigational new drug application. A collagen-induced arthritis (CIA) mouse model of RA was established in DBA/1 J mice. Mice from the treatment assessment group were given a tail vein infusion of hUC-MSC 24 days after primary RA induction, while control assessment (CA) group mice were given cell-free carrier solution. All animals were evaluated daily for RA symptoms via clinical scoring, blood was taken periodically for cytokine analysis, and mice were dissected at end point for histological analysis. A linear mixed model was used to compare the rate of change among groups. The clinical scores of TA group were significantly reduced compared with CA group (P < 0.01), indicating therapeutic effects. The histological scores of the joints in TA group were significantly lower than those in the CA group (P < 0.05), but had no significant difference compared with Healthy groups (P > 0.05). The concentration of (interleukin) IL-6 in TA group was significantly reduced by 80.0% (P < 0.0001) 2 days after treatment and by 93.4% at the experimental endpoint compared with levels prior to hUC-MSC injection. A single intravenous infusion of hUC-MSC (2 × 10(6) cells/mouse), to CIA-induced DBA/1 J mice, resulted in significant alleviation of RA symptoms and may provide significant therapeutic benefits in humans. SAGE Publications 2020-10-14 /pmc/articles/PMC7784581/ /pubmed/33054324 http://dx.doi.org/10.1177/0963689720965896 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Liu, Linan
Farhoodi, Henry P.
Han, Menglu
Liu, Guangyang
Yu, Jingxia
Nguyen, Lily
Nguyen, Brenda
Nguyen, Agnes
Liao, Wenbin
Zhao, Weian
Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis
title Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis
title_full Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis
title_fullStr Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis
title_full_unstemmed Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis
title_short Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis
title_sort preclinical evaluation of a single intravenous infusion of huc-msc (bx-u001) in rheumatoid arthritis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784581/
https://www.ncbi.nlm.nih.gov/pubmed/33054324
http://dx.doi.org/10.1177/0963689720965896
work_keys_str_mv AT liulinan preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT farhoodihenryp preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT hanmenglu preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT liuguangyang preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT yujingxia preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT nguyenlily preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT nguyenbrenda preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT nguyenagnes preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT liaowenbin preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis
AT zhaoweian preclinicalevaluationofasingleintravenousinfusionofhucmscbxu001inrheumatoidarthritis